Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Cancer Chemotherapy and Pharmacology|October 17, 2018
Awakening the "guardian of genome": reactivation of mutant p53Akshay Binayke, Sarthak Mishra, Prabhat Suman, et al.
Journal of Cancer Research and Therapeutics|April 11, 2025
Correlation of immune profiling and exceptional response to immune checkpoint inhibitor in a patient with head and neck cancerKriti Jain, Deepak K Rathore, Surajit Ganguly, et al.
European Journal of Immunology|August 5, 2025
Testosterone Suppresses IL-17 Expression by Targeting RORγt FunctionsAkshay Binayke, Rajdeep Dalal, Charu Suri, et al.
Frontiers in Oncology|July 23, 2025
Cytokine profiling identifies circulating IL-2, IL23 and sPD-L1 as prognostic biomarkers for treatment outcomes in non-small cell lung cancer patients undergoing anti-PD1 therapyKriti Jain, Anika Goel, Deepa Mehra, et al.
Nature Communications|July 10, 2023
IL-9 aggravates SARS-CoV-2 infection and exacerbates associated airway inflammationSrikanth Sadhu, Rajdeep Dalal, Jyotsna Dandotiya, et al.
Vaccine|March 21, 2024
Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort studyArchana Sasi, Jyotsna Dandotiya, Jyotsana Kaushal, et al.
European Journal of Immunology|April 24, 2024
SARS-CoV-2 infection induces thymic atrophy mediated by IFN-γ in hACE2 transgenic miceZaigham Abbas Rizvi, Srikanth Sadhu, Jyotsna Dandotiya, et al.
Vaccines|October 27, 2022
Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19Akshay Binayke, Aymaan Zaheer, Jyotsna Dandotiya, et al.
NPJ Vaccines|January 3, 2024
A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validationAkshay Binayke, Aymaan Zaheer, Siddhesh Vishwakarma, et al.
IJID Regions|November 17, 2025
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical studySubhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
Pageof 2